ExeVir Bio

Share on: 
Website: ExeVir Bio
Business Area(s): 
Description: 

ExeVir develops single-domain antibody-based therapies that help patients ward off viral infections. Their lead drug candidate is in accelerated development as a COVID-19 therapeutic. VHH are single-domain antibody fragments derived from camelids. Their lead compound, an enhanced variant of VHH72-FC, binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell.

Location(s): 
Zwijnaarde
Belgium